Intrac Inc. (ITRD.OB) And Innovative Drug Delivery Systems, Inc. (IDDS) Release: Pivotal Phase II/III Study Shows Dyloject(TM) Significantly Reduces Moderate-To-Severe Post-Operative Pain
10/19/2005 5:09:32 PM
NEW YORK--(BUSINESS WIRE)--July 12, 2005--Intrac, Inc. (OTC BB: ITRD.OB) and its wholly-owned subsidiary Innovative Drug Delivery Systems (IDDS) announced today that a pivotal European Phase II/III study of Dyloject(TM) (diclofenac sodium injection) met its primary endpoint of superior pain relief over 4 hours compared to placebo and therapeutic non-inferiority to Voltarol(R).
According to Dr Daniel Carr, chief executive officer and chief medical officer, IDDS: "For years clinicians have pursued ways to boost pain relief and reduce the dose of morphine needed to control acute, moderate-to-severe pain. Diclofenac has proven safety and efficacy, but until now there has been no way to give it as a single intravenous dose to patients unable to swallow tablets after operations or trauma. Dyloject(TM) -- like IDDS's other products candidates - offers a simple, safe, cost-effective answer to complex analgesic questions."
comments powered by